Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015 (2015), Article ID 681456, 9 pages
http://dx.doi.org/10.1155/2015/681456
Research Article

Osteoarticular Expression of Musashi-1 in an Experimental Model of Arthritis

1Department of Pathology and IBIMER, School of Medicine, University of Granada, 18012 Granada, Spain
2The Spanish Institute of Social Security (INSS), 18006 Granada, Spain
3Oral Surgery and Implant Dentistry Department, School of Dentistry, University of Granada, 18017 Granada, Spain
4Plastic Surgery Department, Virgen de las Nieves University Hospital, 18014 Granada, Spain
5Periodontics Department, School of Dentistry, University of Granada, 18017 Granada, Spain
6Parasitology and Biomedicine López-Neyra Institute, CSIC, 18016 Armilla, Granada, Spain
7Orthopedic Surgery Department, San Cecilio University Hospital of Granada, 18012 Granada, Spain

Received 23 September 2014; Revised 11 January 2015; Accepted 20 January 2015

Academic Editor: Monica Fedele

Copyright © 2015 Francisco O’Valle et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. D. Anthony and T. M. Haqqi, “Collagen-induced arthritis in mice: an animal model to study the pathogenesis of rheumatoid arthritis,” Clinical and Experimental Rheumatology, vol. 17, no. 2, pp. 240–244, 1999. View at Google Scholar · View at Scopus
  2. M. Feldmann, F. M. Brennan, and R. N. Maini, “Role of cytokines in rheumatoid arthritis,” Annual Review of Immunology, vol. 14, pp. 397–440, 1996. View at Publisher · View at Google Scholar · View at Scopus
  3. D. D. Brand, A. H. Kang, and E. F. Rosloniec, “Immunopathogenesis of collagen arthritis,” Springer Seminars in Immunopathology, vol. 25, no. 1, pp. 3–18, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. E. Gonzalez-Rey, A. Chorny, F. O'Valle, and M. Delgado, “Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells,” The American Journal of Pathology, vol. 170, no. 1, pp. 263–271, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Feldmann and R. N. Maini, “Anti-TNFalpha therapy of rheumatoid arthritis: what have we learned?” Annual Review of Immunology, vol. 19, pp. 163–196, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. J. C. Beckham, D. S. Caldwell, B. L. Peterson et al., “Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-α, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures,” Journal of Clinical Immunology, vol. 12, no. 5, pp. 353–361, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. F. M. Brennan, D. Chantry, A. Jackson, R. Maini, and M. Feldmann, “Inhibitory effect of TNFα antibodies on synovial cell interleukin-1 production in rheumatoid arthritis,” The Lancet, vol. 2, no. 8657, pp. 244–247, 1989. View at Google Scholar · View at Scopus
  8. X. Sáez-Llorens, H. S. Jafari, K. D. Olsen, H. Nariuchi, E. J. Hansen, and G. H. McCracken Jr., “Induction of suppurative arthritis in rabbits by Haemophilus endotoxin, tumor necrosis factor-α, and interleukin-1β,” Journal of Infectious Diseases, vol. 163, no. 6, pp. 1267–1272, 1991. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Tracey, L. Klareskog, E. H. Sasso, J. G. Salfeld, and P. P. Tak, “Tumor necrosis factor antagonist mechanisms of action: a comprehensive review,” Pharmacology & Therapeutics, vol. 117, no. 2, pp. 244–279, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Dhillon, K. A. Lyseng-Williamson, and L. J. Scott, “Etanercept: a review of its use in the management of rheumatoid arthritis,” Drugs, vol. 67, no. 8, pp. 1211–1241, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. B. Haraoui and V. Bykerk, “Etanercept in the treatment of rheumatoid arthritis,” Therapeutics and Clinical Risk Management, vol. 3, no. 1, pp. 99–105, 2007. View at Google Scholar · View at Scopus
  12. G. J. Thorbecke, R. Shah, C. H. Leu, A. P. Kuruvilla, A. M. Hardison, and M. A. Palladino, “Involvement of endogenous tumor necrosis factor α and transforming growth factor β during induction of collagen type II arthritis in mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 16, pp. 7375–7379, 1992. View at Publisher · View at Google Scholar · View at Scopus
  13. R. O. Williams, M. Feldmann, and R. N. Maini, “Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 89, no. 20, pp. 9784–9788, 1992. View at Publisher · View at Google Scholar · View at Scopus
  14. P. F. Piguet, G. E. Grau, C. Vesin, H. Loetscher, R. Gentz, and W. Lesslauer, “Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor,” Immunology, vol. 77, no. 4, pp. 510–514, 1992. View at Google Scholar · View at Scopus
  15. P. H. Wooley, J. Dutcher, M. B. Widmer, and S. Gillis, “Influence of a recombinant human soluble tumor necrosis factor receptor FC fusion protein on type II collagen-induced arthritis in mice,” Journal of Immunology, vol. 151, no. 11, pp. 6602–6607, 1993. View at Google Scholar · View at Scopus
  16. R. O. Williams, J. Ghrayeb, M. Feldmann, and R. N. Maini, “Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4,” Immunology, vol. 84, no. 3, pp. 433–439, 1995. View at Google Scholar · View at Scopus
  17. Q. T. Wang, Y. J. Wu, B. Huang et al., “Etanercept attenuates collagen-induced arthritis by modulating the association between BAFFR expression and the production of splenic memory B cells,” Pharmacological Research, vol. 68, no. 1, pp. 38–45, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. T. Nagata, R. Kanno, Y. Kurihara et al., “Structure, backbone dynamics and interactions with RNA of the C-terminal RNA-binding domain of a mouse neural RNA-binding protein, Musashi1,” The Journal of Molecular Biology, vol. 287, no. 2, pp. 315–330, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. H. Okano, H. Kawahara, M. Toriya, K. Nakao, S. Shibata, and T. Imai, “Function of RNA-binding protein Musashi-1 in stem cells,” Experimental Cell Research, vol. 306, no. 2, pp. 349–356, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. H. Okano, T. Imai, and M. Okabe, “Musashi: a translational regulator of cell fate,” Journal of Cell Science, vol. 115, no. 7, pp. 1355–1359, 2002. View at Google Scholar · View at Scopus
  21. Y. Kaneko, S. Sakakibara, T. Imai et al., “Musashi1: an evolutionally conserved marker for CNS progenitor cells including neural stem cells,” Developmental Neuroscience, vol. 22, no. 1-2, pp. 139–153, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. S. M. Sureban, R. May, R. J. George et al., “Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo,” Gastroenterology, vol. 134, no. 5, pp. 1448–1458, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. T. Fukui, H. Takeda, H.-J. Shu et al., “Investigation of Musashi-1 expressing cells in the murine model of dextran sodium sulfate-induced colitis,” Digestive Diseases and Sciences, vol. 51, no. 7, pp. 1260–1268, 2006. View at Publisher · View at Google Scholar · View at Scopus
  24. X. Liu, W. T. Yang, and P. S. Zheng, “Msi1 promotes tumor growth and cell proliferation by targeting cell cycle checkpoint proteins p21, p27 and p53 in cervical carcinomas,” Oncotarget, vol. 5, no. 21, pp. 10870–10885, 2014. View at Google Scholar
  25. M. Delgado, C. Abad, C. Martinez, J. Leceta, and R. P. Gomariz, “Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease,” Nature Medicine, vol. 7, no. 5, pp. 563–568, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. K. Kannan, R. A. Ortmann, and D. Kimpel, “Animal models of rheumatoid arthritis and their relevance to human disease,” Pathophysiology, vol. 12, no. 3, pp. 167–181, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. G. Cho, M. L. Cho, S. Y. Min, and H. Y. Kim, “Type II collagen autoimmunity in a mouse model of human rheumatoid arthritis,” Autoimmunity Reviews, vol. 7, no. 1, pp. 65–70, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. Holmdahl, L. Jansson, E. Larsson, K. Rubin, and L. Klareskog, “Homologous type II collagen induces chronic and progressive arthritis in mice,” Arthritis & Rheumatism, vol. 29, no. 1, pp. 106–113, 1986. View at Publisher · View at Google Scholar · View at Scopus
  29. A. M. Malfait, R. O. Williams, A. S. Malik, R. N. Maimi, and M. Feldman, “Chronic relapsing homologous collageninduced arthritis in DBA/1 mice as a model for testing diseasemodifying and remissioninducing therapies,” Arthritis & Rheumatism, vol. 44, no. 5, pp. 1215–1224, 2001. View at Publisher · View at Google Scholar
  30. J. M. Stuart, M. A. Cremer, A. S. Townes, and A. H. Kang, “Type II collagen-induced arthritis in rats. Passive transfer with serum and evidence that IgG anticollagen antibodies can cause arthritis,” Journal of Experimental Medicine, vol. 155, no. 1, pp. 1–16, 1982. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Holmdahl, M. E. Andersson, T. J. Goldschmidt et al., “Collagen induced arthritis as an experimental model for rheumatoid arthritis. Immunogenetics, pathogenesis and autoimmunity,” APMIS, vol. 97, no. 7, pp. 575–584, 1989. View at Publisher · View at Google Scholar · View at Scopus
  32. R. O. Williams, “Rodent models of arthritis: relevance for human disease,” Clinical and Experimental Immunology, vol. 114, no. 3, pp. 330–332, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. S. Rose, M. Eren, S. Murphy et al., “A novel mouse model that develops spontaneous arthritis and is predisposed towards atherosclerosis,” Annals of the Rheumatic Diseases, vol. 72, no. 1, pp. 89–95, 2013. View at Publisher · View at Google Scholar · View at Scopus
  34. A. V. Misharin, G. K. Haines III, S. Rose, A. K. Gierut, R. S. Hotchkiss, and H. Perlman, “Development of a new humanized mouse model to study acute inflammatory arthritis,” Journal of Translational Medicine, vol. 10, no. 1, article no. 190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. A. H. Tremouler and S. Albani, “Novel therapies for rheumatoid arthritis,” Expert Opinion on Investigational Drugs, vol. 15, no. 11, pp. 1427–1441, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. J. J. Goronzy and C. M. Weyand, “Rheumatoid arthritis,” Immunological Reviews, vol. 204, no. 1, pp. 55–73, 2005. View at Publisher · View at Google Scholar · View at Scopus
  37. E. Gonzalez-Rey, R. Martínez-Romero, F. O'Valle et al., “Therapeutic effect of a poly(ADP-ribose) polymerase-1 inhibitor on experimental arthritis by downregulating inflammation and Th1 response,” PLoS ONE, vol. 2, no. 10, Article ID e1071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. R. O. Williams, “Collagen-induced arthritis in mice: a major role for tumor necrosis factor-α,” Methods in Molecular Biology, vol. 361, pp. 265–284, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. J. Zwerina, S. Hayer, M. Tohidast-Akrad et al., “Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction,” Arthritis and Rheumatism, vol. 50, no. 1, pp. 277–290, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. K. E. Donahue, G. Gartlehner, D. E. Jonas et al., “Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis,” Annals of Internal Medicine, vol. 148, no. 2, pp. 124–134, 2008. View at Publisher · View at Google Scholar · View at Scopus
  41. L. W. Moreland, S. W. Baumgartner, M. H. Schiff et al., “Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein,” The New England Journal of Medicine, vol. 337, no. 3, pp. 141–147, 1997. View at Publisher · View at Google Scholar · View at Scopus
  42. L. W. Moreland, M. H. Schiff, S. W. Baumgartner et al., “Phase III trial of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNFR: Fc, ENBREL),” Journal of Investigative Medicine, vol. 46, p. 228A, 1998, Abstract. View at Google Scholar
  43. É. Toussirot and D. Wendling, “The use of TNF-α blocking agents in rheumatoid arthritis: an overview,” Expert Opinion on Pharmacotherapy, vol. 5, no. 3, pp. 581–594, 2004. View at Publisher · View at Google Scholar · View at Scopus
  44. J. M. Sutherland, E. A. McLaughlin, G. R. Hime, and N. A. Siddall, “The Musashi family of RNA binding proteins: master regulators of multiple stem cell populations,” Advances in Experimental Medicine and Biology, vol. 786, pp. 233–245, 2013. View at Publisher · View at Google Scholar · View at Scopus
  45. T. Takahashi, H. Suzuki, T. Imai et al., “Musashi-1 post-transcriptionally enhances phosphotyrosine-binding domain-containing m-Numb protein expression in regenerating gastric mucosa,” PLoS ONE, vol. 8, no. 1, Article ID e53540, 2013. View at Publisher · View at Google Scholar · View at Scopus